Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centers

Adalimumab (ADA) was approved in Italy for the treatment of ulcerative colitis (UC) unresponsive to standard treatments in 2014, but no data from real life are currently available. The aim of the present study was to assess the real-life efficacy and safety of ADA in managing UC outpatients in some...

Descripción completa

Detalles Bibliográficos
Autores principales: Tursi, Antonio, Elisei, Walter, Faggiani, Roberto, Allegretta, Leonardo, Valle, Nicola Della, Forti, Giacomo, Franceschi, Marilisa, Ferronato, Antonio, Gallina, Sara, Larussa, Tiziana, Luzza, Francesco, Lorenzetti, Roberto, Mocci, Giammarco, Penna, Antonio, Rodino’, Stefano, Sebkova, Ladislava, de Medici, Antonio, Pranzo, Giuseppe, Ricciardelli, Cristina, Grasso, Giuseppina, Scorza, Stefano, Zampaletta, Costantino, Picchio, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112877/
https://www.ncbi.nlm.nih.gov/pubmed/30142791
http://dx.doi.org/10.1097/MD.0000000000011897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112877/
https://www.ncbi.nlm.nih.gov/pubmed/30142791
http://dx.doi.org/10.1097/MD.0000000000011897

Ejemplares similares